Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agents. - Wikidata - awgldk - TriplyDB

Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agents.

Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agents.

http://www.wikidata.org/entity/Q46702563

about

Impact of selective platelet inhibition in reducing cardiovascular risk - role of vorapaxar High-resolution crystal structure of human protease-activated receptor 1 Thrombin receptors and their antagonists: an update on the patent literature Safety and efficacy of targeting platelet proteinase-activated receptors in combination with existing anti-platelet drugs as antithrombotics in mice Protease-activated receptors in cancer: A systematic review.Antiplatelet and antithrombin strategies in acute coronary syndrome: state-of-the-art review.Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more.Kallikreins and proteinase-mediated signaling: proteinase-activated receptors (PARs) and the pathophysiology of inflammatory diseases and cancer.Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis.PAR-1 inhibitor antiplatelet agents: performance below par?SCH 530348: a novel oral thrombin receptor antagonist.The modification of natural products for medical use.Mechanism of action and clinical development of platelet thrombin receptor antagonists.Atopaxar: a review of its mechanism of action and role in patients with coronary artery disease.The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day.Industrial applications of the Diels-Alder reaction.Updates in antiplatelet agents used in cardiovascular diseases.Vorapaxar in atherosclerotic disease management.Proteinases, Their Extracellular Targets, and Inflammatory Signaling.Neutrophil elastase and proteinase-3 trigger G protein-biased signaling through proteinase-activated receptor-1 (PAR1).Modulation of PAR(1) signalling by benzimidazole compounds.A State Transition Model for Health Outcomes Associated with Vorapaxar Treatment as an Add-on to Standard Care Antiplatelet Therapy in the Prevention of Thrombotic Events for Patients with a Recent Myocardial Infarction.Discovery of Octahydroindenes as PAR1 Antagonists.Himbacine-derived thrombin receptor antagonists: c7-aminomethyl and c9a-hydroxy analogues of vorapaxar.Himbacine-derived thrombin receptor antagonists: c7-spirocyclic analogues of vorapaxar.Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial.Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease.Structure-based QSAR, molecule design and bioassays of protease-activated receptor 1 inhibitors.Total Synthesis of (+)-Sarcophytin.Total Synthesis of the Diterpenoid (+)-Harringtonolide.Exploring the Phe-Gly dipeptide-derived piperazinone scaffold in the search for antagonists of the thrombin receptor PAR1.Synthesis of novel and potent vorapaxar analogues.Octahydrocyclopenta[c]pyridine and octahydrocyclopenta[c]pyran analogues as a protease activated receptor 1 (PAR1) antagonist.Targeting Platelet G Protein-Coupled Receptors for Antithrombotic Therapy Antiplatelet drugs

P2860

Q26745754-FF41D2C2-C9BB-4353-96E6-F6EAED1284C1 Q27675402-A932CBBB-605E-40BA-AE94-3371AC91FFD6 Q28281696-E3598FED-ED02-47CA-8EA1-1823846EFD30 Q36110533-1AD4C9CE-6640-4355-A8E3-4565B6F51B39 Q36121203-EA0149B1-7F2F-426C-A6A7-4B1545B334F7 Q36302146-A7E403DA-8AA2-452D-8CD9-242D4B1BDD25 Q37024500-F0F40B7E-DC0A-416E-8429-E7B4FDE5F7A8 Q37216583-55179BDA-D2E3-41A1-83FE-774997E1CAFE Q37322052-AE8363CE-D4F2-4CB5-A64A-45B6308EFAA8 Q37387238-00BF1622-BCB6-4AA0-954D-F87ED57A8C1E Q37588688-6AC1A528-8BAD-47E1-A8C8-1B4433688CAF Q37689655-A06AB375-B273-403A-B642-6BC189C74D6D Q37776518-4C493618-FAF1-4B12-84DE-D1B16C26FFEC Q38032614-0810D421-F488-46B5-9843-E42DA554E3C1 Q38053481-044D9149-3140-41E4-8253-5A70201A4D41 Q38085293-81747FA2-E21A-4B87-920F-28002DFC0696 Q38161394-2D95FEF0-E838-467A-8229-8CAF07B91D9C Q38355060-89DA963F-F8EE-4E63-9467-D394A4A93646 Q38966192-87FEA8D4-F17D-4AFE-8F13-EC5953D0BF3F Q39093865-62E30B97-1E1C-4365-89FC-630D8349D4B2 Q39361791-B3C2B075-89D7-43C9-B98E-E860656A04E7 Q39709613-3C151BDA-9AA0-4D95-B515-9736B3158238 Q39780296-BB0293B1-8539-4BC3-B5ED-D93923E33533 Q39785506-A83D3338-12F6-4C16-8EB4-763C66805756 Q39785906-8A90B02F-D137-453C-8676-2CD271D09ECD Q40898988-5CE36081-F3ED-4331-9801-E42DCDF378E4 Q42635425-79ADD969-4075-444C-9E3F-755149085AB7 Q47639646-B9E97230-AE51-4BFE-8640-227E8027EF25 Q48196266-6073B9C0-30BB-4D31-AB14-616C29113081 Q51198106-269E4CAA-A435-4EAB-BE66-9D621B28A759 Q51740874-892132CE-5798-45BC-A2E7-2E3E6311716A Q53159606-5DA88902-DB03-441C-8330-692CB5B48B11 Q53212869-1EAAA32D-B1B4-4F8E-90D4-6FA3617DD5E5 Q58291538-A6CDC223-AECE-4EB6-A263-EDC219E36155 Q58481433-1F6DE45E-9219-4A64-A7A8-54079727A7D6

P2860

Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agents.

http://www.wikidata.org/entity/Q46702563

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Discovery of potent orally act ...... s novel antithrombotic agents.

@en

Discovery of potent orally active thrombin receptor

@nl

type

label

Discovery of potent orally act ...... s novel antithrombotic agents.

@en

Discovery of potent orally active thrombin receptor

@nl

prefLabel

Discovery of potent orally act ...... s novel antithrombotic agents.

@en

Discovery of potent orally active thrombin receptor

@nl

P1433

Q46702563-86DA8CC3-88DA-43FD-98E9-BB39C6DEB157

P1476

Q46702563-39F11AA5-9405-4A7D-ACA0-0CEF23D85C54

P2093

Q46702563-004A9740-0608-40F4-81C1-1B1C7003ABE8

Q46702563-14765949-E16C-4284-B66E-DD5EC38D110D

Q46702563-19DC432F-5D4D-4FF6-B731-DF49B552908E

Q46702563-23556699-26C9-45B2-89AB-41F9D85984CF

Q46702563-23A87589-0F61-408D-99EA-10569D8265E3

Q46702563-2E50E085-09A5-4534-A80C-196254240A27

Q46702563-2EDA4F40-2BA6-4511-AD1B-FB4DD0D48FD6

Q46702563-4AFF67DE-B1B2-4747-B3FD-D63BF17853A8

Q46702563-4F4BDE5E-6B71-43DD-B6D5-5204C85A1178

Q46702563-54405838-12E4-4D58-B4A1-248351458670

P304

Q46702563-94DA2968-DEE5-4D54-BD24-817A16DB6E6E

P31

Q46702563-959CC42E-9129-45BC-A746-EDC4BE96EB6A

P356

Q46702563-8C1DBEBF-7DF5-447B-908E-ADD6905C2D14

P407

Q46702563-E1A16BA3-6E80-485F-ABD6-CEDFEB01A6B1

P433

Q46702563-A9874B75-A4B9-40B5-8090-248517F92762

P478

Q46702563-E44FD304-AC95-4630-925E-D57C1C9B06D2

P577

Q46702563-63B620E7-6CEF-4C34-B905-05AD8725468C

P698

Q46702563-112D21A2-A431-4431-8615-77BD91C00F20

P356

P1433

Journal of Medicinal Chemistry

P1476

Discovery of potent orally act ...... s novel antithrombotic agents.

@en

P2093

Carolyn Foster

http://www.w3.org/2001/XMLSchema#string

Darìo Doller

http://www.w3.org/2001/XMLSchema#string

George Boykow

http://www.w3.org/2001/XMLSchema#string

Ho-Sam Ahn

http://www.w3.org/2001/XMLSchema#string

Hsingan Tsai

http://www.w3.org/2001/XMLSchema#string

Jacqueline Agans-Fantuzzi

http://www.w3.org/2001/XMLSchema#string

Janice Lau

http://www.w3.org/2001/XMLSchema#string

Madhu Chintala

http://www.w3.org/2001/XMLSchema#string

Martin Clasby

http://www.w3.org/2001/XMLSchema#string

Matthew Bryant

http://www.w3.org/2001/XMLSchema#string

P304

5884-5887

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/JM0502236

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P577

2005-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16161991

http://www.w3.org/2001/XMLSchema#string